Publication Exclusive: Fallout from failed clinical trials poses challenges to companies

So far in 2015, four different ophthalmic products in phase 3 clinical trials failed to meet their primary endpoints. Ocular Surgery News spoke with three of these companies to find out what happened and how they responded. Their stories offer a telling glimpse at the challenges and opportunities companies face when endpoints are missed in clinical trials as part of the overall innovation cycle.“Private companies often simply learn from their experience and make appropriate adjustments to their research and business plan. They continue on as long as their investors are optimistic they will eventually create value,” OSN Chief Medical Editor Richard L. Lindstrom, MD, said. “Public companies must disclose any material event in a timely fashion and usually see a significant fall in their share price, usually in the 20% to 50% range, but it can be even more if it is an FDA trial not approved by a panel.”